Soliqua 100/33 Now Available for Adults with Type 2 Diabetes

Soliqua showed statistical superiority in HbA1c change from baseline to Week 30 vs. Lantus (insulin glargine)
Soliqua showed statistical superiority in HbA1c change from baseline to Week 30 vs. Lantus (insulin glargine)

Sanofi announced the launch of Soliqua 100/33 (insulin glargine and lixisenatide injection) for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (<60 Units daily) or lixisenatide. 

Soliqua contains insulin glargine 100 Units/mL and lixisenatide 33mcg/mL. In a clinical trial, Soliqua showed statistical superiority for the change in HbA1c from baseline to Week 30 (P<0.0001) vs. Lantus (insulin glargine).  

Related Articles

Soliqua, which combines a long-acting human insulin analog with a glucagon-like peptide-1 (GLP-1) receptor agonist, was initially approved by the Food and Drug Administration (FDA) in November 2016. Insulin glargine lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It also inhibits lipolysis and proteolysis, and enhances protein synthesis. Lixisenatide increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying.

Soliqua 100/33 is available as a single prefilled 3mL SoloStar pen in 5-count packages. Soliqua delivers doses ranging from 15–60 Units with each injection.

For more information call (800) 633-1610 or visit Soliqua 100-33.com.